Illumina, Inc. vs Invesco Solar ETF — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Invesco Solar ETF trades at $53.29. The key difference: Illumina, Inc. is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | TAN | |
|---|---|---|
Market Cap | $28.96B | — |
Sector | Health | Sector/Thematic |
52-Week High | $205.10 | $73.95 |
52-Week Low | $91.00 | $36.62 |
Enterprise Value | $30.32B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
TAN trades at $52.75, up 2.93% today amid positive solar sector news. Technical indicators are bearish overall, with moving averages signaling caution and RSI-6 suggesting overbought conditions. Recent tariffs on imported solar products have boosted sentiment, but the ETF faces headwinds from high volatility and regulatory uncertainty.
The outlook is mixed: supportive policies may drive growth, yet valuation concerns and interest rate sensitivity pose risks. Investors should weigh exposure to utility-scale solar growth against sector volatility and top-heavy holdings.
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →